Jacek Kubica
Jacek Kubica is an expert in Cardiology at Nicolaus Copernicus University (Poland). As of October 2026, ScienceLeadR ranks Jacek Kubica in the top 1% of experts worldwide for Myocardial Ischemia, Coronavirus Infections and COVID-19. Jacek Kubica has authored 441 publications, the most recent in 2026, and is an investigator in 32 clinical trials, 2 of them ongoing. SLR score: 1,922 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Biochemistry - Internal Medicine - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 441
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Beyond ejection fraction: why post-MI heart failure needs AI-driven care. PMID 42845189 — heart failure, heart, cardiovascular diseases, cardiology, artificial intelligence | Cardiol J | 2026 | 0 |
| Dual antithrombotic therapy with dabigatran and ticagrelor in patients with acute coronary syndrome and non-valvular atrial fibrillation undergoing percutaneous coronary intervention (ADONIS-PCI): protocol for a randomized controlled pilot trial. PMID 42770881 — stents, pilots, embolism, hemorrhage, stroke, ticagrelor, percutaneous coronary intervention, acute coronary syndrome, aspirin, atrial fibrillation, coronary artery bypass, therapeutics, dabigatran | Cardiol J | 2026 | 0 |
| From monitoring to meaning: why artificial intelligence will redefine heart failure care. PMID 42725699 — intelligence, heart failure, heart, cardiovascular diseases, cardiology, artificial intelligence | Cardiol J | 2026 | 0 |
| Myocardial infarction redefined: mechanism matters more than type. PMID 42721024 — myocardial infarction, cardiovascular diseases | Cardiol J | 2026 | 0 |
| State of the Art: Personalized Antiplatelet Therapy by Genotype and Platelet Function Testing. PMID 42554288 — research design, genetic testing, hemorrhage, clopidogrel, cardiac catheterization, genotype, therapeutics, blood platelets | Catheter Cardiovasc Interv | 2026 | 0 |
Clinical Studies 32
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment NCT05905965 — waist-hip ratio, therapeutics, metabolic syndrome | Phase 3 | Recruiting | 2023 |
| Evaluation of Safety and Efficacy of Two Ticagrelor based De escalation Antiplatelet Strategies in Acute Coronary Syndrome NCT04718025 — safety, ticagrelor, acute coronary syndrome, aspirin, st elevation myocardial infarction, therapeutics, non-st elevated myocardial infarction, angina, unstable | Phase 3 | Recruiting | 2022 |
LeadR Networks
Main global connection map